Tolerogenic function of dimeric forms of HLA-g recombinant proteins: A comparative study in Vivo

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Favier, Benoit ^a,b   HoWangYin, Kiave Yune ^a,b,c   Wu, Juan ^d   Caumartin, Julien ^a,b   Daouya, Marina ^a,b   Horuzsko, Anatolij ^d   Carosella, Edgardo D ^a,b   Le Maoult, Joel ^a,b  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN HLA G1 ANTIGEN IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; BETA 2 MICROGLOBULIN HLA G5 ANTIGEN FUSION PROTEIN; HLA G ANTIGEN; HLA G ANTIGEN ALPHA 1 DOMAIN IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA-G ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN; PEPTIDE;

ALLOGRAFT; ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIMERIZATION; ELECTROPHORESIS; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; SKIN GRAFT; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HELA CELL; IMMUNOLOGY; METABOLISM; SKIN TRANSPLANTATION;

MURINAE;

ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS; IMMUNOPRECIPITATION; MICE; MICE, INBRED C57BL; PEPTIDES; RECOMBINANT FUSION PROTEINS; SKIN TRANSPLANTATION;

EID: 79960310753     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021011     Document Type: Article

References (36)

1. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Le Maoult J, (2008) Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 111: 4862-4870.
2. Carosella ED, Moreau P, Le Maoult J, Rouas-Freiss N, (2008) HLA-G: From biology to clinical benefits. Trends Immunol 29: 125-132.
3. Lila N, Carpentier A, Amrein C, Khalil-Daher I, Dausset J, et al. (2000) Implication of HLA-G molecule in heart-graft acceptance. Lancet 355: 2138.
4. Rouas-Freiss N, Le Maoult J, Moreau P, Dausset J, Carosella ED, (2003) HLA-G in transplantation: a relevant molecule for inhibition of graft rejection? Am J Transplant 3: 11-16.
5. Wiendl H, Behrens L, Maier S, Johnson MA, Weiss EH, et al. (2000) Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neurol 48: 679-684.
6. Aractingi S, Briand N, Le Danff C, Viguier M, Bachelez H, et al. (2001) HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? Am J Pathol 159: 71-77.
7. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, et al. (1998) HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 95: 4510-4515.
8. Pangault C, Le Friec G, Caulet-Maugendre S, Lena H, Amiot L, et al. (2002) Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases. Hum Immunol 63: 83-90.
9. Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, et al. (2007) Human Neuroblastoma Cells Trigger an Immunosuppressive Program in Monocytes by Stimulating Soluble HLA-G Release. Cancer Res 67: 6433-6441.
10. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H, (2005) HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105: 1694-1698.
11. Kren L, Muckovaa K, Lzicarovab E, Sovac M, Vybihalc V, et al. (2010) Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: A role in innate immunity? Journal of Neuroimmunology 220: 131-135.
12. Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, et al. (2005) Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol 159: 155-164.
13. Lozano JM, Gonzalez R, Kindelan JM, Rouas-Freiss N, Caballos R, et al. (2002) Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule. Aids 16: 347-351.
14. Chen H-X, Chen B-G, Shi W-W, Zhen R, Xu D-P, et al. (2010) Induction of cell surface HLA-G expression in pandemic H1N1 2009 and seasonal H1N1 influenza virus infected patients. Human Immunology In Press, Accepted Manuscript.
15. Huang J, Burke P, Yang Y, Seiss K, Beamon J, et al. (2010) Soluble HLA-G Inhibits Myeloid Dendritic Cell Function in HIV-1 Infection by Interacting with Leukocyte Immunoglobulin-Like Receptor B2. J Virol 84: 10784-10791.
16. Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, et al. (2001) HLA-G2,-G3, and-G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 166: 5018-5026.
17. Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED, (1997) The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci USA 94: 5249-5254.
18. Le Maoult J, Krawice-Radanne I, Dausset J, Carosella ED, (2004) HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci USA 101: 7064-7069.
19. Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, et al. (2006) Soluble HLA-G Inhibits Cell Cycle Progression in Human Alloreactive T Lymphocytes. J Immunol 176: 1331-1339.
20. Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, et al. (2007) Trogocytosis-based generation of suppressive NK cells. EMBO J 26: 1423-1433.
21. Ristich V, Liang S, Zhang W, Wu J, Horuzsko A, (2005) Tolerization of dendritic cells by HLA-G. Eur J Immunol 35: 1133-1142.
22. Liang S, Ristich V, Arase H, Dausset J, Carosella ED, et al. (2008) Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway. Proc Natl Acad Sci U S A 105: 8357-8362.
23. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, et al. (2010) Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 116: 935-944.
24. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, et al. (1997) A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 186: 1809-1818.
25. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, et al. (1998) Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 160: 3096-3100.
26. Rajagopalan S, Long EO, (1999) A Human Histocompatibility Leukocyte Antigen (HLA)-G-specific Receptor Expressed on All Natural Killer Cells. J Exp Med 189: 1093-1100.
27. Gonen-Gross T, Achdout H, Gazit R, Hanna J, Mizrahi S, et al. (2003) Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol 171: 1343-1351.
28. Boyson JE, Erskine R, Whitman MC, Chiu M, Lau JM, et al. (2002) Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci USA 99: 16180-16185.
29. Lila N, Amrein C, Guillemain R, Chevalier P, Latremouille C, et al. (2002) Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 105: 1949-1954.
30. Horuzsko A, Lenfant F, Munn DH, Mellor AL, (2001) Maturation of antigen-presenting cells is compromised in HLA-G transgenic mice. Int Immunol 13: 385-394.
31. Liang S, Baibakov B, Horuzsko A, (2002) HLA-G inhibits the functions of murine dendritic cells via the PIR-B immune inhibitory receptor. Eur J Immunol 32: 2418-2426.
32. Rebmann V, Le Maoult J, Rouas-Freiss N, Carosella ED, Grosse-Wilde H, (2005) Report of the Wet Workshop for Quantification of Soluble HLA-G in Essen, 2004. Human Immunology 66: 853-863.
33. Greten TF, Korangy F, Neumann G, Wedemeyer H, Schlote K, et al. (2002) Peptide-[beta]2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. Journal of Immunological Methods 271: 125-135.
34. Shiroishi M, Kuroki K, Ose T, Rasubala L, Shiratori I, et al. (2006) Efficient Leukocyte Ig-like Receptor Signaling and Crystal Structure of Disulfide-linked HLA-G Dimer. J Biol Chem 281: 10439-10447.
35. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, et al. (2003) Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA 100: 8856-8861.
36. Shiroishi M, Kuroki K, Rasubala L, Tsumoto K, Kumagai I, et al. (2006) Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). PNAS 103: 16412-16417.